<DOC>
	<DOC>NCT01958645</DOC>
	<brief_summary>A study to investigate the safety, tolerability and pharmacodynamics of MEDI8111 after single ascending doses in healthy male.</brief_summary>
	<brief_title>To Assess Safety, Tolerability and Pharmacodynamics of Intravenous MEDI8111 After Single Ascending Doses.</brief_title>
	<detailed_description>A phase I, single-blind, randomised, placebo-controlled, single centre study to investigate the safety, tolerability and pharmacodynamics of intravenous MEDI8111 after single ascending doses in healthy male subjects.</detailed_description>
	<criteria>Provision of signed and dated, written informed consent prior to any study specific procedures, Healthy male subjects aged 1840 years with suitable veins for cannulation or repeated venepuncture, Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weight at least 50 kg an no more than 100 kg inclusive, Male subjects should be willing to avoid fathering a child by either true abstinence or the use of two effective means of contraception from the day of dosing until 3 months after dosing with the IP. They should also be willing to use barrier methods from the day of dosing until 3 months after dosing. Prothrombotic mutation such as factor V Leiden, or deficiencies of protein C, protein S, prothrombin, antithrombin or APC, Antibodies to coagulation FII, History or family history of venous or arterial thromboembolic event, and/or myocardial infarction before age of 50 years, ETP level at baseline &gt;2000nM/min, FII level (by clot) at screening and/or at baseline outside 50250% of the normal range</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Phase 1, healthy male subjects, safety and tolerability, pharmacodynamic, pharmacokinetic</keyword>
</DOC>